News
BioConnection congratulates BioLineRx with their FDA approval of Aphexda
BioConnection congratulates BioLineRx with their FDA approval of Aphexda. We are proud that we have been able to support BioLineRx since the start...
Dutch CDMO BioConnection announces substantial investment by Gimv, supported by existing shareholders
New capital secures growth acceleration in services for small to medium sized biopharmaceutical companies and further enhancement of quality control...
BioConnection to manufacture clinical trial material for Nykode Therapeutics’ vaccine
Oss, The Netherlands, 29 November 2021 BioConnection, an independent CDMO (Contract Development Manufacturing Organization) based in Oss, The...
GMP certification for new large scale filling line
Oss, The Netherlands, June 28, 2021. BioConnection received today from the Dutch Healthcare Inspectorate (IGJ) the GMP certification and...
BioConnection is honoured to support VarmX
With the EU and US GMP capabilities from our facility in Oss, BioConnection is proud to assist VarmX to accelerate the GMP manufacturing trajectory...
AdaptVac partners with BioConnection to manufacture their COVID-19 vaccine
BioConnection announces that it is collaborating with AdaptVac for the Drug Product manufacture of their COVID-19 vaccine in its...
BioConnection is honoured that AIMM Therapeutics has become our customer.
With our capabilities from our facility in Oss, the Netherlands, we are able to assist AIMM Therapeutics in the development of their groundbreaking...
Announcement: Large scale sterile GMP production capacity available for COVID-19 programs in our EMA and US-FDA certified facility
BioConnection B.V. / Oss, The Netherlands BioConnection has sterile drug product production capacity available for COVID-19 programs BioConnection...
Announcement: Sterile GMP production capacity available to overcome Covid-19 pandemic
BioConnection B.V. / Oss, The Netherlands / April 9, 2020 BioConnection has sterile production capacity available for the battle against the...
Lava Therapeutics and BioConnection cooperate to improve cancer treatment
BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific...
Covid-19 update
Oss, The Netherlands, March 18, 2020. BioConnection has taken precautions related to the global outbreak of the Covid-19 virus. To start with; we...
BioConnection invests in expansion of its current production capacity with a second production line
Oss, The Netherlands, April 8, 2019. BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the...